Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.

Precis Engineering + Architecture , an award-winning design firm with locations in Ambler, PA, and Cary, NC, has hired Veera ...

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Prime Medicine will streamline research in a bid to focus on what its executives believe to be its most high-value programs, the company said Monday. “We’re not going to push all of these programs ...

The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.